Does the measurement of systolic longitudinal myocardial strain and ultrasensitive troponin I predict subsequent cardiotoxicity in patients with breast cancer treated with anthracyclines, taxanes, and trastuzumab?
Systolic longitudinal myocardial strain and ultrasensitive troponin I can help predict and potentially avoid subsequent cardiotoxicity in breast cancer patients undergoing cardiotoxic chemotherapy.
In patients with breast cancer treated with anthracyclines, taxanes, and trastuzumab, systolic longitudinal myocardial strain and ultrasensitive troponin I measured at the completion of anthracyclines therapy are useful in the prediction of subsequent cardiotoxicity and may help guide treatment to avoid cardiac side-effects.
Sawaya et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: